ziftomenib (KO-539) / University of Michigan, Kura Oncology  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ziftomenib (KO-539) / Kura Oncology
2019-001545-41: First in human clinical trial of the study drug KO-539 in patients with leukemia

Not yet recruiting
1/2
236
Europe
ziftomenib, KO-539, Capsule, hard
Kura Oncology, Inc., KURA ONCOLOGY INC, Kura Oncology, Inc.
Relapsed and/or refractory Acute Myeloid Leukemia, Relapsed and/or refractory leukemia, Diseases [C] - Cancer [C04]
 
 
KOMET-001, NCT04067336: First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
199
Europe, Canada, US
Ziftomenib
Kura Oncology, Inc.
Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia
09/24
09/25
NCT05848687: TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Recruiting
1/2
90
US
Dexamethasone, Mitoxantrone, PEG asparaginase, Bortezomib, Vorinostat, Mercaptopurine, Methotrexate, Blinatumomab, Ziftomenib
Tanja Andrea Gruber, Pediatric Oncology Experimental Therapeutics Investigators' Consortium, Amgen, Lucile Packard Foundation for Children's Health, Kura Oncology, Inc.
Lymphoblastic Leukemia
12/28
12/33

Download Options